If you take any other medication — blood pressure pills, thyroid hormones, birth control, insulin, blood thinners, or antidepressants — read this before starting weight loss treatment.
More than 70% of adults who qualify for weight loss medication take at least one other prescription drug. Many take three or more. That creates a web of potential interactions that your prescribing provider should evaluate — but that you should understand too.
This guide covers the seven most common drug interaction categories for weight loss medications, organized by risk level. We cover GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), phentermine, Contrave (naltrexone/bupropion), Qsymia (phentermine/topiramate), and orlistat.
GLP-1 receptor agonists slow gastric emptying — that's partly how they reduce appetite. But slower stomach emptying also delays how quickly other oral medications move into your small intestine for absorption. For drugs with narrow therapeutic windows (where too much or too little causes problems), this delay matters. It doesn't always mean danger, but it does mean your medication levels may shift in ways that require monitoring.
If you have type 2 diabetes and already take insulin or sulfonylureas (glipizide, glyburide, glimepiride), adding a GLP-1 medication creates real hypoglycemia risk. Both your existing diabetes drugs and the new GLP-1 lower blood sugar — and the combined effect can drop glucose dangerously low.
Clinical guidelines call for reducing sulfonylurea doses by 50% when starting a GLP-1 agonist. Insulin doses typically need a 20% reduction at initiation, with further adjustments based on glucose monitoring. Your endocrinologist or prescriber should build a tapering plan before you take your first dose.
Metformin, on the other hand, has minimal interaction risk with GLP-1s. It works through a different mechanism (reducing hepatic glucose output rather than stimulating insulin), and hypoglycemia from the combination is uncommon. Many patients safely take both.
Shakiness, sweating, rapid heartbeat, confusion, irritability, dizziness, or sudden hunger. If you take insulin or sulfonylureas alongside a GLP-1, keep fast-acting glucose (tablets, juice) accessible at all times — especially during the first 4–6 weeks and during dose escalation.
Levothyroxine (Synthroid, Levoxyl) has a narrow therapeutic window and is highly sensitive to absorption conditions. It must be taken on an empty stomach, 30–60 minutes before eating, because even small amounts of food reduce how much gets absorbed.
GLP-1 medications complicate this in two ways. First, delayed gastric emptying gives levothyroxine a longer transit time in the GI tract, which can actually increase absorption. Clinical trials with oral semaglutide showed a 33% increase in levothyroxine exposure when the two were taken together. Second, as you lose weight, your body needs less thyroid hormone — a dose that was correct at 240 lbs may be too high at 200 lbs.
Case reports have documented patients on stable levothyroxine doses for years suddenly developing symptoms of hyperthyroidism (racing heart, anxiety, sweating, weight loss beyond what the GLP-1 would explain) after starting semaglutide. Some required 25% dose reductions. A 2025 target trial emulation using Medicare data found that GLP-1 initiation in levothyroxine users significantly increased the risk of atrial fibrillation/flutter — likely from undetected thyroid hormone over-replacement.
Check TSH levels 6–8 weeks after starting a GLP-1, and again after each dose escalation. Continue monitoring every 2–3 months for the first year. If you take oral semaglutide specifically, take your levothyroxine at a consistent time relative to your semaglutide dose. Consistency matters more than the exact timing.
This is mostly good news. GLP-1 medications actually lower blood pressure on their own — the landmark SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide. That's a benefit, not a risk.
The concern is additive hypotension. If your blood pressure is already well-controlled on amlodipine, lisinopril, or another antihypertensive, adding a GLP-1 that further lowers it could push you too low. About 1% of Wegovy patients in clinical trials developed clinically significant low blood pressure. Symptoms include dizziness when standing, lightheadedness, and fatigue.
The practical implication: as you lose weight and your blood pressure improves, you may need to reduce — or even stop — your antihypertensive medications. This is a good problem to have, but it requires monitoring. Home blood pressure devices cost $25–$50 and give you weekly data your provider can use to adjust doses.
For a deeper look at how GLP-1s affect cardiovascular health, see our guide on weight loss medication and blood pressure.
This is where the specific GLP-1 you take matters enormously.
Tirzepatide (Mounjaro/Zepbound) significantly reduces oral contraceptive absorption. The manufacturer's prescribing information documents a roughly 20% decrease in overall exposure to oral hormonal contraceptives. Their recommendation: use a backup barrier method (condoms, diaphragm) for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or switch to a non-oral contraceptive method entirely.
Semaglutide (Ozempic/Wegovy) studies have not shown clinically significant effects on oral contraceptive levels. The delayed absorption timing (Tmax) shifts slightly, but overall exposure remains within the therapeutic window. No dose adjustment or backup method is recommended in semaglutide prescribing information.
Regardless of which GLP-1 you take, non-oral contraceptives — IUDs, implants, patches, injections — bypass the digestive system entirely and are unaffected by delayed gastric emptying. For any woman starting GLP-1 therapy, these are the most reliable options.
Beyond the direct birth control interaction, GLP-1-driven weight loss improves fertility — especially in women with PCOS. Weight loss reduces insulin resistance, which can restore ovulation in women who weren't ovulating regularly. This means you might become fertile faster than expected, even if birth control absorption isn't affected. Plan accordingly and discuss contraception with your provider before starting treatment.
For the full breakdown, read our dedicated guide: GLP-1 Medications and Birth Control.
Warfarin has a narrow therapeutic window, so any change in absorption timing raises flags. GLP-1 medications delay warfarin's peak concentration (Tmax) due to slower gastric emptying. However, pharmacokinetic studies show that overall warfarin exposure (AUC and Cmax) generally remains within the therapeutic range. Dulaglutide showed a 22% Cmax reduction, but this wasn't considered clinically relevant.
Current evidence does not recommend adjusting warfarin doses when starting a GLP-1. However, closer INR monitoring during the first 4–8 weeks is prudent — check INR weekly during dose titration rather than monthly.
Direct oral anticoagulants (DOACs) like apixaban (Eliquis) and rivarelbaan (Xarelto) have wider therapeutic margins and are less affected by absorption timing changes. If you're on a DOAC, the interaction risk is lower, though informing your prescriber remains important.
The antidepressant/weight loss medication landscape is nuanced because some antidepressants cause weight gain (potentially blunting GLP-1 effects), while others actively support weight loss.
SSRIs (sertraline, fluoxetine, paroxetine, etc.): These can cause 5% or more weight gain over time, which may partially counteract GLP-1 therapy. However, there are no significant direct pharmacokinetic interactions between GLP-1 agonists and SSRIs/SNRIs. GLP-1 receptors exist in mood-regulating brain regions, and some patients report improved mood on GLP-1 therapy — possibly from the weight loss itself, possibly from direct neurological effects.
Bupropion (Wellbutrin): This is the one antidepressant that actually promotes weight loss. It's an ingredient in Contrave (naltrexone/bupropion), an FDA-approved weight loss medication. Taking a standalone GLP-1 alongside bupropion is generally safe and may even enhance weight loss — but don't take Contrave and a GLP-1 together without specific guidance from your prescriber, as the combined appetite-suppression effect may be excessive.
Contrave-specific warning: Contrave carries a black box warning for suicidality related to the bupropion component. It's also contraindicated with opioid use (naltrexone blocks opioid receptors), seizure disorders, and should not be combined with MAOIs. If you're on an MAOI antidepressant, Contrave is off the table.
For more on this topic, see our article on weight loss medication and mental health.
Alcohol doesn't interact with GLP-1 medications through a traditional pharmacokinetic pathway. There's no FDA black box warning. But the clinical picture is more complex than "it's fine."
GLP-1s slow gastric emptying, which delays alcohol absorption — you may feel fine for longer, then get hit harder as your body processes the alcohol. A 2025 pilot study found that GLP-1 users had a delayed rise in breath alcohol concentration compared to controls, followed by higher peak levels. A separate Yale study found that GLP-1s reduce the liver enzyme (Cyp2e1) that metabolizes alcohol, meaning alcohol stays in your system longer and produces fewer toxic byproducts — potentially protective for the liver, but also meaning you may be over the legal limit longer than expected.
Pancreatitis risk is the real safety concern. Both alcohol and GLP-1s can stress the pancreas independently. Combining them — especially heavy drinking — may increase pancreatitis risk beyond either alone. If you have any history of pancreatitis, your provider should discuss alcohol limits explicitly.
For Contrave users: The interaction is more serious. Bupropion lowers the seizure threshold, and alcohol further lowers it. The prescribing information strongly warns against alcohol use with Contrave.
For phentermine users: Both phentermine and alcohol are CNS-active. Combined use can cause unpredictable sedation or agitation. Avoidance is recommended.
We cover this in depth in our dedicated article: Can You Drink Alcohol on Weight Loss Medication?
Orlistat (Alli, Xenical) works entirely differently from GLP-1s — it blocks fat absorption in the gut by inhibiting pancreatic lipase. Its interaction profile is unique: it can reduce absorption of fat-soluble vitamins (A, D, E, K) and may affect the absorption of levothyroxine, cyclosporine, and some anticoagulants. If you take orlistat, separate it from fat-soluble vitamin supplements by at least 2 hours, and take levothyroxine at least 4 hours apart.
Qsymia combines phentermine with topiramate. The topiramate component brings its own interaction concerns: it's a carbonic anhydrase inhibitor that can increase the risk of kidney stones when combined with other carbonic anhydrase inhibitors (like acetazolamide). It can also reduce the effectiveness of oral contraceptives and increase the sedation effect of CNS depressants (benzodiazepines, sleep aids, alcohol). Topiramate is a known teratogen — Qsymia is absolutely contraindicated in pregnancy, with mandatory negative pregnancy tests before starting.
| Co-Medication | GLP-1s | Contrave | Qsymia | Orlistat |
|---|---|---|---|---|
| Insulin / Sulfonylureas | High risk — reduce dose | Low risk | Low risk | Monitor glucose |
| Levothyroxine | Monitor TSH closely | Low risk | Low risk | Separate by 4 hrs |
| Blood pressure meds | Monitor — additive BP lowering | Low risk | Low risk | No interaction |
| Oral birth control | Tirzepatide: backup needed | Low risk | Reduced effectiveness | No interaction |
| Warfarin | Monitor INR | Low risk | Low risk | Monitor INR |
| SSRIs / SNRIs | Generally safe | Watch seizure threshold | Additive CNS effects | No interaction |
| Alcohol | Enhanced sensitivity | Seizure risk — avoid | CNS depression risk | Worse GI effects |
| Opioids | No major interaction | Contraindicated | Additive sedation | No interaction |
Drug interactions aren't always predictable from a chart. Your kidney function, liver function, age, body weight, and the specific combination of everything you take all factor in. This is precisely why reputable telehealth weight loss providers run medication reviews before prescribing — and why the cheapest, fastest option isn't always the safest one.
The providers we recommend all include medication review as part of their intake process:
Comprehensive medication review included
Full medical intake with pharmacist review of current medications before prescribing. Particularly strong for patients with complex medication regimens.
Check Availability →Physician-led consultations
Board-certified providers who evaluate your complete medication list and health history before recommending treatment.
Learn More →GLP-1 programs with medical monitoring
Includes ongoing check-ins to adjust dosing and monitor for interactions — especially important during the titration phase when most interaction issues surface.
Get Started →From $175 — weight loss consultations
Affordable provider access for patients who need a thorough medication review but want to keep costs manageable.
Book Consultation →Before your first appointment — whether in-person or telehealth — prepare a complete list of every medication you take, including over-the-counter drugs, supplements, and vitamins. Don't forget to mention any herbal supplements (some, like St. John's Wort, have significant drug interactions). Include dosages and how long you've been taking each one.
Ask your provider specifically: "Which of my current medications might need dose adjustments after I start weight loss treatment?" If they can't answer that question clearly, consider whether they're the right provider for your situation.